BioSpace News Archive

nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the secondary endpoints for the nanoMesh™ Pathogen Inhibiting Protein (PIP) uptake studies.

Kane Biotech Inc., announced that, at the annual and special meeting of shareholders of Company held on May 26, 2021, by ordinary resolution, a majority of the Shareholders approved the adoption of the performance and restricted share unit plan of the Company and the amended and restated stock option plan of the Company, including a majority of disinterested Shareholder approval with respect to the PRSU Plan.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced that it has adjourned its 2021 Annual Meeting of Stockholders due to a lack of quorum.

Histogen Inc. announced the closing of its previously announced registered direct offering for the issuance and sale of 5,977,300 shares of its common stock, at a purchase price of $1.10 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021.

Translate Bio reported that on June 7, 2021, the Company granted non-qualified stock options to purchase an aggregate of 238,200 shares of the Company’s common stock to fifteen new employees.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), today announced that the Company conducted its 2021 annual stockholders meeting (the “Annual Meeting”) and adjourned the meeting solely with respect to Proposal 2 set forth in its Definitive Proxy Statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on April 26, 2021.

MediWound Ltd. (Nasdaq: MDWD), today announced that the enrollment target of patients for an interim assessment of its EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been achieved, and interim assessment is expected by the end of July 2021.

Gravity Diagnostics has partnered with the Commonwealth of Kentucky to provide a COVID-19 testing drive-thru located at 302 W 4th St Parking in Covington, Kentucky.

WuXi XDC (“XDC”), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, “LCB”), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in development and manufacturing of antibody-drug conjugates (ADCs).